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Abstract
Background: Storage of leftover biosamples generates rich biobanks for future studies, saving time and money and limiting
physical impact to sample donors.
Objective: To investigate the attitudes of Chinese patients and the general public on providing consent for storage and use
of leftover biosamples.
Design, Setting and Participants: Cross-sectional surveys were conducted among randomly selected patients admitted to a
Shanghai city hospital (n=648) and members of the general public (n=492) from May 2010 to July 2010.
Main Outcome Measures: Face-to-face interviews collected respondents-report of their willingness to donate residual
biosample, trust in medical institutions, motivation for donation, concerns of donated sample use, expectations for research
results return, and so on.
Results: The response rate was 83.0%. Of the respondents, 89.1% stated that they completely understood or understood
most of questions. Willingness to donate residual sample was stated by 64.7%, of which 16.7% desired the option to
withdraw their donations anytime afterwards. Only 42.3% of respondents stated they ‘‘trust’’ or ‘‘strongly trust’’ medical
institutions, the attitude of trusting or strongly trusting medical institutions were significantly associated with willingness to
donate in the general public group.(p,0.05) The overall assent rate for future research without specific consents was also
low (12.1%). Hepatitis B virus carriers were significantly less willing than non-carriers to donate biosamples (32.1% vs. 64.7%,
p,0.001).
Conclusions: Low levels of public trust in medical institutions become serious obstacle for biosample donation and
biobanking in China. Efforts to increase public understanding of human medical research and biosample usage and trust in
the ethical purposes of biobanking are urgently needed. These efforts will be greatly advanced by the impending legislation
on biobanking procedures and intent, and our results may help guide the structure of such law.
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Introduction
Human biological material, including tissues, blood and other
body fluids and excretions, has emerged as an important tool for
biomedical research [1], often supplementing and sometimes
replacing the animal or cell culture based research models. The
biobanks that store such samples are rapidly evolving into rich
resources for new and on-going studies, providing biosamples that
may be investigated by new next generation technologies or
reassessed as validation cohorts in established studies. Moreover,
biobanks are particularly useful for scientists and clinicians lacking
direct access to human specimens or a large enough condition-
specific donor population. However, the inception of the
biobanking industry raised many ethical and legal concerns and
much governmental effort worldwide has been focused on
establishing appropriate laws and regulations. China, in particular,
has yet to pass such legislation, and even the informed consent
process for initial donation of biosamples is relatively new.
Ultimately, the success of such legislation and the public’s
willingness to participate in biosample donation and biobanking
will be affected by issues of informed consent type (broad or
specific) [2–4], benefit sharing [5,6], individual privacy protection
[7], information access [8,9] and public trust [9,10].
The recent phenomenon of globalization has corresponded with
a trend towards resource sharing. Biobanks are often sought out
for international collaborations so that researchers may obtain
more diverse and larger sample sets, thus generating more
clinically applicable results [11]. Unfortunately, the current
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concerning biobanks, especially in countries like China, present
serious obstacles for international medical research efforts [1,12].
Recently, however, it has been raised to establish broad guidelines
on conducting ethical and appropriate international biobank
research [12,13]. China is the world’s most populated country,
and as such has the potential to generate the world’s largest human
biobank. The feasibility of such an endeavor remains unknown
due to the paucity of data on the citizen’s attitudes towards
biosample donation and storage. If the majority is unwilling to
donate or consent to biobanking, China may not only lose out on
international collaborations but also hinder human health
advances worldwide. Strong legislation for biobanking will not
only serve to ensure international collaborators of the integrity of
Chinese biosamples and the Chinese research efforts involving
other nations’ biosamples, but also provide justification for greater
public trust in biobanking.
To address these issues, we conducted cross-sectional surveys of
Chinese attitudes towards biosample donation and human medical
research. The surveys were carried out among hospital patients
and the general public. Qualitative data from face-to-face
interviews was assessed to determine willingness to donate
biosamples and consent to biobanking, and to identify the factors
influencing compliance or resistance.
Methods
Ethics Statement
The study was approved by the ethics committee of Renji
hospital, and the survey qualified as involving only ‘‘minimal risks’’
to participants. The survey was completely anonymous and
questionnaire responses were not linked with the participants’
identification in survey process, so we didn’t obtained informed
consent. However, a verbal informed consent regarding the goals
of the study and the willingness to participate was given to the
potential respondents. This procedure was approved by the ethics
committee of Renji hospital.
Participant recruitment and selection
Two groups were enrolled in the study: hospital patients with
diverse medical conditions and individuals from the general
public.
Patients were recruited between May 2010 and June 2010 at the
Shanghai Renji hospital, a university-affiliated teaching general
hospital in Shanghai’s Pudong district with more than two-million
outpatients attended annually. Patients were recruited from each
of 16 outpatient departments and had traveled from 12 provinces
to seek treatment. Patients were selected for recruitment by using a
random number table. The only inclusion criterion for study
enrollment was age $16 years. Any critically ill patient who was
unable to make decisions independently was excluded from
participation.
The general public group was recruited between June 2010 and
July 2010 in two rural communities (Waigang in West Shanghai,
and Yinhang in North Shanghai) and three urban communities
(Tangqiao, Jinyang and Weifang in central Shanghai city).
Participants were selected for recruitment by using multistage
stratified probability sampling; communities were selected at the
first stage, followed by household addresses selected at the second
stage and recruitment of all individuals $16 years living at a single
address. Stratification was based on geographic areas. The face-to-
face interviews were mainly conducted on Saturday or Sunday in
community health centers, in order to avoid over-representation of
unemployed individuals. Any individuals unable to care for
themselves and to make decisions independently were excluded
from enrollment.
The questionnaire and the survey process
The survey was composed of questions aimed to determine the
respondents’ willingness to donate residual biosamples to a
biobank, trust in medical institutions, motivation for donation,
concerns of donated sample use, expectations for research results
return, and perceptions about future research consent and
commercial research. The survey questions were designed
according to relevant literature review and the results from a
pre-survey. The pre-survey was composed of 11 open-ended
queries and was conducted on 50 patients and 44 general public
members. The subsequent formal survey included all the 11
queries, which were related to the following contents: 1.
Willingness to donate (Likert scales). 2. Donation withdrawal
(Likert scales). 3. Concerns about donation (open-ended). 4. Level
of trust in medical institutions (Likert scales). 5. Most trusted
institutions (open-ended). 6. Motivation for donation (open-
ended). 7. Anonymous donation (Likert scales). 8. Individual
results return (Likert scales). 9. Willingness to donate for profit-
making research (Likert scales). 10. Consent for future research
(Likert scales). 11. Understanding of the above questions (Likert
scales). (See details in figure legends and table footnotes)
The survey process was facilitated by face to face interviews by
using questionnaire in a small, private room. We totally had four
interviewers and each interviewer was trained for five times to
ensure they understood this survey enough. For each training
session, we read 2–3 related paper carefully. Finally, the outline of
the interview and every question of the questionnaire were
discussed adequately. The interview outline is as follows: 1. Value
of the biosample derived from human body. 2. Current situation of
biosample donation. 3. Protection of donors’ identities. 4.
Explanation of the hypothetical scenario (see below). 5. Read
and explain the questions in questionnaire. The respondents were
asked to indicate their willingness to donate biosamples to an
existing biobank (Renji biobank, established in 2008) based on the
following hypothetical scenario: ‘‘The doctors at this hospital plan
to carry out medical research on a type of cancer treatment. If you
were a cancer patient, would you be willing to donate the leftover
biosample from your diagnosis or surgical treatment for this
research?’’
All verbal portions of the survey were conducted in plain
Chinese. For the close-ended questions (with multiple choice
answers), respondents read the options, and then gave verbal
answers that were recorded by the interviewers. If the respondents
were illiterate, one of the interviewers would read aloud both the
questions and answer options. Features of every question were
discussed adequately to ensure understanding of a respondent’s
intent, and respondents were given the opportunity to ask
questions freely. Interviews lasted between 10 and 15 minutes.
At the end, every participant was asked to indicate their
understanding of all the questions in the survey by using a 5-
point Likert scale that ranged from ‘‘totally understood’’ to ‘‘totally
did not understand’’.
Statistical analysis
The associations of donation willingness, expectation for the
research results to be returned to the individual, willingness to give
future research consent, and current trust in medical institutions
with demographic and other attitudinal factors were determined
by comparing proportions and prevalence ratios using the Chi-
square test. If a statistical significance of 0.05 or less was detected,
it would be entered into a regression model. Multiple logistic
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factors associated with people’s willingness or their other
preferences. This multivariable statistical analysis yields the ratios
of willingness adjusted for all other confounding variables included
in the regression analysis. Consent was coded as ‘‘1’’, while
consent denial and undecided was coded ‘‘0’’; thus, the odds ratios
were interpreted as the odds of consent. The tests were two-tailed,
and p,0.05 was considered significant. All data analyses were
performed with the Statistical Package for the Social Sciences,
version 16.0 (SPSS, Chicago, IL, USA). Data was plotted by
Sigmaplot, version 11.0 (Systat Software, San Jose, CA, USA).
Results
Response rates and respondents characteristics
In total, 648 patients and 492 general public members (age
range: 16–82 years) were enrolled. Of those, 531 (81.9%) patients
and 415 (84.3%) general public members completed the
questionnaire. The unanswered questions on this survey varied
from 0 to 7 (mean, 2.1). The respondents’ general characteristics
are shown in Table S1.
Willingness to donate
About 64.7% of respondents (67.0% of patients and 61.7% of
general public members) were willing to donate their tissue for
research, while 28.9% (25.2% and 33.5%, respectively) refused to
donate and 6.4% (7.7% and 4.8%, respectively) were undecided.
Of those willing to donate, 16.7% (16.9% and 16.4%, respectively)
stated a desire to withdraw their donations afterwards. The
patients were slightly more willing to donate than the general
public members, but the difference was not statistically significant
(67.0% vs. 61.6%, p=0.08). The respondents from urban areas
were, however, significantly more willing to donate than the rural
respondents (71.65% vs. 45.96%, p,0.001), probably due to
higher education levels for the urban people (college or higher
education: 49.21% vs. 42.24%), although the difference was not
significant (p=0.16).
Willingness to donate residual sample differed significantly by
age, employment, and educational level in both the patient and
general public groups. Respondents who were younger, students,
company employed, or had a higher education level were more
willing to donate residual biosamples (Table S1). The willingness
to donate a residual biosample was independently associated with
an individual’s trust in medical institutions, hepatitis B virus-
negative status, or having no concerns about the donation
(concern #9) (p,0.05) (Table 1).
Consent for future research or profit-making research
There was an overall low assent rate (12.1%) for future research
without specific consent (Figure 1a). No demographic or
attitudinal factor was independently associated with consent for
future research (data not shown). As for attitudes about profit-
making research, only 34.3% of all willing donors expressed
agreement to their sample being used for profit-making research.
Patients were more willing to donate for profit-making research
(p,0.05) (Figure 1a).
Expectation for research results to be returned to the
individual
Most respondents (74.3%) wanted to have the research results
obtained from their individual donated sample to be returned to
them (Figure 1a). No significant differences were found between
those wanting research results returned among the general public
members (75.0%) or hospital patients (73.9%) (Table S1). Being
company employed, however, was significantly associated with
wanting research results returned (Odds ratio: 2.98, 95% CI:
1.26–7.02, p=0.01).
Concerns about biosample donation
The respondents indicated nine types of concerns, which are
listed in Figure 1b. Patients were more concerned about ‘‘more
tissue would be taken for research than was needed’’ (#1)
(p,0.05), while general people were more concerned about
‘‘donation might cause potential ethical issues’’ (#5) (p,0.05)
(Figure 1b). Lack of concern (#9) was found to be independently
associated with willingness to donate in both the patient and
general public groups. The concern types involving dangerous
research (#3) and ethical issues (#5) were significantly associated
with unwillingness to provide biosamples in the general public
group (p,0.05) (Table 1).
Trust in medical institutions
Only 42.3% of total respondents stated that they ‘‘trust’’ or
‘‘strongly trust’’ medical institutions to manage their donations
properly (Figure 1a), while 43.9% of respondents stated ‘‘neutral’’
and 13.8% stated either ‘‘mistrust’’ or ‘‘strongly mistrust’’.
Respondents who chose ‘‘trust’’ or ‘‘strongly trust’’ were
significantly more likely to have no concern about the biosample
donation, as compared to those who chose ‘‘mistrust’’ or ‘‘strongly
mistrust’’ (21.5% vs. 0.8%, p,0.001). Only one respondent didn’t
trust medical institutions and chose the option ‘‘I have no concern
about donation’’. Given the choice of which type of institutions
were most trustworthy to manage biosamples, the majority of
respondents chose hospital research institutions (37.7%), followed
closely by Chinese medical association (34.6%), and government
institutions (30.3%). Only 4.7% of the total respondents chose
management by ethics committee or IRB, and even fewer (2.0%)
chose the for-profit company research institutions (Figure 1c).
Patients were more likely to trust hospital research institutions
(p,0.05), while general people were more likely to trust
government institutions (p,0.05) (Figure 1c).
After adjusting for potentially confounding factors, the attitude
of trusting medical institutions were significantly associated with
willingness to donate in the general public group (p,0.05)
(Table 1).
Motivation for donation
Most willing donors reported their motivation as being ‘‘to
benefit future patients’’ (66.5%), with the next most common
attitude being ‘‘it’s my obligation’’ (34.6%). Fewer of the general
public members agreed with the motivation ‘‘to establish a good
relationship with medical institutions’’ than did the patients, but
the difference was not statistically significant (6.74% vs. 3.90%,
p=0.13) (Figure 1d).
Attitudes of respondents with stigmatizing health
conditions
We surveyed four kinds of potentially stigmatizing health
conditions: hypertension, diabetes mellitus, hepatitis B, and
depression (Table S1). Respondents with the stigmatizing health
conditions were less willing to donate their leftover tissue than
those without (51.1% vs. 64.7%, p,0.001). However, when the
respondents with hepatitis B were removed from the analysis of
stigmatizing health conditions vs. unaffected individuals the
significant difference was lost (59.8% vs. 64.7%, p=0.20).
Hepatitis B is a chronic infectious disease with high incidence in
China. One hundred and sixty-eight respondents (8.9%) in this
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significantly less willing to donate biosamples than those with
any other stigmatizing health conditions, among both the patient
and general public groups (p,0.05) (Table S1).
Participants’ understanding of the survey questions
Of the total respondents, 45.1% stated they understood the
questionnaire completely, while 45.2% stated they understood
more than two-thirds of the questions. Only 7.0% stated that they
were only able to understand about one-half of the questions, and
2.6% stated that they had understood less than one-third or none
of the questions at all.
Discussion
Although the ownership of donated biosamples remains a
controversial subject, it is recognized that patients have the
autonomy to determine the present and future use of their
donations. Respect for autonomy is one of the fundamental
guidelines in biosample donation management, and doctors should
carefully interact with their patients to facilitate an informed
choice being made without influencing the patient’s decision.
Patients’ confidence can only be maintained and further developed
if health care professionals attach more importance to their
autonomy. Members of the general public are the potential
biosample donors, respect for autonomy not only promote the
public trust in biobanks and medical institutions, but also
encourage them to donate biosamples. Since biobank legislation
aims to ensure respect of donors’ autonomy and protect them from
potential harm (whether it be physical or perceived) [14], it is
necessary to understand the donors’ attitudes towards biosample
donation and specific concerns.
This is the first study to examine attitudes of Chinese patients
and general public members towards donating and biobanking
biological samples. The overall results revealed a low willingness to
donate, a low level of trust in medical institutions and ethics
committees, and a low assent rate for future research without
specific consent. The diversity of our study participants (patient/
general public, urban/rural, ranges of existing medical conditions
and age) corresponded with all the people who are potential
biosample donors.
Principal findings and differences with other studies
The level of willingness to donate found in our study (64.7%)
was lower than that reported by other similar studies in the
literature (70–90%) [15–19]. Furthermore, 16.7% of our respon-
dents who were willing to donate said they would withdraw their
donations at some point in the future; hence, the actual number of
Table 1. Results of multiple logistic regressions examining demographic and attitudinal differences in preferences to donate
biosample.
p Odds ratio 95% CI
Patients Age Age ,0.001 0.96 0.94–0.98
Stigmatizing health
conditions
Hepatitis B virus carriers(yes/no) ,0.001 0.22 0.09–0.48
Do you trust medical
institutions
Strongly trust 0.81 - -
Trust 0.76 - -
General RE - -
Mistrust 0.04 0.40 0.17–0.94
Strongly mistrust 0.003 0.19 0.07–0.56
Concerns* Concern #1(yes/no) 0.03 2.00 1.06–3.76
Concern #9(yes/no) ,0.001 14.19 3.96–50.81
General public Geographic areas Rural areas ,0.001 0.38 0.22–0.66
Urban areas RE
Stigmatizing health
conditions
Hepatitis B virus carriers(yes/no) 0.004 0.20 0.07–0.60
Do you trust medical
institutions
Strongly trust 0.07 - -
Trust 0.03 1.96 1.09–3.52
General RE - -
Mistrust 0.88 - -
Strongly mistrust 0.96 - -
Concerns* Concern #3(yes/no) 0.04 0.45 0.21–0.97
Concern #5(yes/no) 0.04 0.40 0.17–0.97
Concern #9(yes/no) 0.001 8.98 2.58–31.23
Demographic items were excluded from this table if none was statistically significant. Except age, all variables were entered into the models as categorical variables.
CI: Confidence Interval.
RE: Reference.
*: Concern 1–9: 1: more tissue would be taken for research than was needed. 2: my confidentiality would be lost. 3: donations might be used in research that is
dangerous to me or others. 4: donation might spread my disease. 5: donation might cause potential ethical issues. 6: I do not trust the intent of medical institutions. 7: I
haven’t thought about donation. 8: it’s bad for my health. 9: no concern.
doi:10.1371/journal.pone.0036050.t001
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one-half. In addition, people being surveyed were just put into the
hypothetical position of cancer patients, which might make them
more willing to donate, making the low rates even more striking.
The results showed that respondents with higher education
levels were more willing to donate biosamples. The finding was
similar to the study reported among the general population in
USA [20]. Our survey also revealed that unwillingness to donate
in the Chinese population was based on a general low level of trust
of medical institutes and hepatitis B virus-positive status. Public
trust has been previously identified as a significant influencing
factor for the individual’s decision to provide a biosample donation
[5]; it is generally believed that securing public trust and
confidence is a necessary step towards ensuring the long-term
viability of biobanks [21]. Because most biobanks in China were
established by hospitals in the past few years, and the survey on
patients was conducted in the hospital and it was based on the
hypothesis that the biosamples would be stored at an existed
biobank hosted by the hospital. So we examined the respondents’
trust in medical institutions (hospital) in this study and we found
that only 42.3% of total respondents trusted medical institutions to
manage their donations properly. Decreased confidence in
medical institutions over time will likely have damaging conse-
quences on biosample donation.
We would like to speculate on the causes of this loss in public
trust of the medical institutions in China. Several possible reasons
Figure 1. The results of x
2-tests examining the differences in attitudes and perceptions between patients and general public
members. *: P,0.05. a. Statements 1–7: 1: I’m willing to donate the residual sample. 2: I trust medical institutions. 3: I would want to withdraw my
donation afterwards. 4: I would want to donate anonymously. 5: I would want to know my individual result. 6: I would like my sample to be used for
profit-making research. 7: I would not like my sample to be used for future research without my specific consent. b. Concerns about donation of
biosample 1–9: 1: more tissue would be taken for research than was needed. 2: my confidentiality would be lost. 3: donations might be used in
research that is dangerous to me or others. 4: donation might spread my disease. 5: donation might cause potential ethical issues. 6: I do not trust the
intent of medical institutions. 7: I haven’t thought about donation. 8: it’s bad for my health. 9: no concern. c. Trusted institutions 1–8: 1: university
research institutions. 2: hospital research institutions. 3: for-profit company research institutions. 4: ethics committee or IRB. 5: Chinese medical
association. 6: government research institutions (such as, the health bureau). 7: no trusted institutions. 8: other institutions. d. Motivation for donation
1–7: 1: to establish a good relationship with medical institutions. 2: it’s my obligation. 3: to benefit future patients. 4: to benefit me and my family.5 :
no motivation. 6: can’t think of a reason to refuse. 7: other motivation.
doi:10.1371/journal.pone.0036050.g001
Attitudes towards Residual Biosample Donation
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36050immediately come to mind. First, the unequal health care system.
Health care has become the number-one cited concern of China’s
population in recent years [22]. However, the high out-of-pocket
cost and limited insurance coverage [23] had caused a disparity in
access to healthcare. In addition, the health workforce is
maldistributed among the nation, physically limiting access to
some (rural) populations and widening the gap in health status
across the nation [24]. This situation has been compounded by
Chinese popular media outlets reporting sensationalized stories of
medical malpractice, causing the public’s mistrust of doctors and
hospitals [25]. In addition, many patients believe that doctors
provide multiple tests in order to obtain additional benefits from
their employers or insurers, while doctors have defensively argued
that these tests are confirmatory and actually protect patients from
misdiagnosis [25]. Unfortunately, the current trust between
doctors and patients is eroded, and the physician-patient
relationship is entering a vicious circle in China.
In the present study, respondents who trusted medical
institutions were more willing to donate biosamples, which might
be due to their lack of concern about the eventual use or outcome
of the donation. The respondents’ trust was found to be strongest
in hospital research institutions, the Chinese medical association
and government’s institutions. A minimal amount of respondents
(4.7%) preferentially trusted an ethics committee or IRB. It is
possible that the respondents mistrust the management role for
ethics committees, but it is also possible that they were most
familiar with hospitals, and that most did not truly understand
what an ethics committee or an IRB were. However, this finding
may also reflect the ethics committee or IRBs not having
contributed significant activities to the general public. China’s
ethics committee and IRBs should do more to increase their
influence, especially for those not completely independent of their
affiliated research institutes.
Previous studies have found that people with stigmatizing health
conditions may have different opinions of sample donation [26]. In
this study, Respondents with the stigmatizing health conditions
were less willing to donate their leftover tissue than those without.
However, when the respondents with hepatitis B were removed
from the analysis, the significant difference was lost. In China, an
estimated 120 million people are infected with hepatitis B virus
[27], accounting for 10% of the total population. In recent years,
many hepatitis B virus carriers have experienced discrimination in
the workplace or in social situations, and this trend appears to be
increasing. In this survey, 8.9% of the respondents were hepatitis B
virus carriers. We found that hepatitis B virus carriers were more
unwilling to donate biosamples than the rest of the respondents.
This sub-population should then be a focus group of programs to
promote confidence in the medical community and human
medical research and of doctors in the efforts to establish more
productive and respectful communications.
Overall, only 12.1% of the respondents preferred the option to
authorize any future research on their individual biosamples. This
percentage was lower than that reported from the other similar
studies in the literature [3,8,28,29]. The general low level of trust
in medical institutions might be a reason why most participants
want to control the future usage of their donations. Thus, specific
informed consent might be a better method than broad consent to
encourage Chinese to donate biosamples; not only will this
approach protect patients’ interests and limit potential access to
personal information, but it will ensure donor autonomy.
Furthermore, by gaining specific consent for every future study
the public trust in biobanks and medical researchers will be
consistently renewed.
The strengths of this study were the high response rate, the
diverse population examined, and the integrity of the data
gathered from face-to-face interviews; however, each of these
features can also represent a weakness of the study. First, the non-
response rate of 17% may have introduced some bias. Second, the
patients were enrolled from only one general hospital in a specific
geographic region, which may limit the generalizability of our
results. Third, approximately 10% of the participants had
difficulty understanding the questions even when fully explained
during the face-to-face interview. In addition, participants’
understanding of the questions was self-assessed which couldn’t
rule out misunderstandings. Finally, the survey on patients was
conducted in hospital, face-to-face questionnaire might underes-
timate the reluctance to donate, and overestimate trust in medical
institutions.
Conclusions and policy implications
The willingness of Chinese patients and general public members
to donate biosamples is low. Low level of trust in medical
institutions has become an obstacle for initial donation and
biobanking for future research. China should take immediate
action to increase public trust in biobanking and willingness to
donate. We believe that the findings from this study have
important implications for China’s biobanks legislation that is
currently being constructed and for future international research
collaborations.
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